Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 743M | 6.1% |
| Gross Profit | 265M | 15.1% |
| Cost of Revenue | 565M | 1.6% |
| Operating expense | 98M | 3.3% |
| Net Income | 136M | 22.2% |
| EBITDA | 169M | 33.9% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 3.68B | 5.3% |
| Total Liabilities | 923M | 1.1% |
| Total Equity | 2.75B | 6.8% |
| Shares Outstanding | 73M | 0.1% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 180M | 9.2% |
| Cash from investing | -82M | 18.9% |
| Cash from financing | -64M | 70.5% |
EPS
Financial Highlights for West Pharmaceutical Services in Q3 '24
West Pharmaceutical Services reported a revenue of 743M, which is a 6.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 265M, marking a 15.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 565M, a 1.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 98M, showing a -3.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 136M, showing a 22.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 169M, showing a 33.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for West Pharmaceutical Services with growth in revenue, gross profit, and net income.
